• Products
  • Suppliers
  • Sourcing Requests
  • Visitor
  • Exhibitor
  • Advertiser
  • Supplier
  • Buyer
  • Buyer
  • Suppliers
  • Advertiser
  • Exhibitor
  • Visitor
CPHI & PMEC China 2024
Content Hub Top Banner
PSI elearn series
Webinars
Pharma Sources Insight
Industry Reports
PharmaVibe 

Webinars

GMP Inspection Situation on Drug Manufacturing Equipment and Management Experience of Russian Inspectorate
GMP Inspection Situation on Drug Manufacturing Equipment and Management Experience of Russian Inspectorate
Date: 19 October 2020
Speaker: Ivan Guliaev
PhD., Head of the Training and Development Division of Inspectorate
Federal State Institution «State Institute of Drugs and Good Practices», Russia
How Indian API Register in China
How Indian API Register in China
Date: 22 June 2020
Speaker: Chengpei Liu
Registration Manager | China Chimopharma
Best Practices in Pharmaceutical Remote Audits During COVID-19 and Beyond
Best Practices in Pharmaceutical Remote Audits During COVID-19 and Beyond
Date: 21 June 2020
Speaker: Jim Fries
CEO of Rx-360
Pharmaceutical Market in China Policy Reform, Impacts and Opportunities
Pharmaceutical Market in China Policy Reform, Impacts and Opportunities
Date: 18 June 2020
Speaker: Dr. Annie Siu
Principal Consultant (Informa)
2019 Deals Review and Deals in China
2019 Deals Review and Deals in China
Date: 18 June 2020
Speaker: Tina Zhao
Life Sciences Solution Consultant, Clarivate
Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page
View More >
Pharma Sources Insight
More
Pharmaceutical Industry in 2024: Flexible Production, Innovative Drugs and Personalized Medicine
Pharmaceutical Industry in 2024: Flexible Production, Innovative Drugs and Personalized Medicine
Download for Free
PSI April 2023: Innovative Drugs Going Aroad
PSI April 2023: Innovative Drugs Going Aroad
Download for Free
PSI June 2022: New Developments, Greater Imapct
PSI June 2022: New Developments, Greater Imapct
Download for Free
Industry Report
Asia Pacific as a Clinical Trials Powerhouse
October 2022
Presented by
Citeline (Pharma Intelligence)
Download
Pharma R&D Annual Review 2022 Supplement: New Active Substances Launched During 2021
October 2022
Presented by
Citeline (Pharma Intelligence)
Download
Pharma R&D Annual Review 2022: Navigating the Landscape
October 2022
Presented by
Citeline (Pharma Intelligence)
Download
The Annual Clinical Trials Round-up 2021-Clinical Trials Resilience After Pandemic Disruptions
October 2022
Presented by
Informa Pharma Intelligence
Download
China Clinical Trials Landscape 2021
September 2021
Presented by
Informa Pharma Intelligence
Download
2021Sustainability in Pharma Packaging, Devices and Manufacturing Report
December 2021
Presented by
CPHI Online
Download
CPhI Pharma 2021 Annual Report- Golden Age for Discovery, Technology and Growth
December 2021
Presented by
CPHI Online
Download
CPhI China and IQVIA Market Prognosis 2021- 2025
September 2021
Presented by
CPhI and IQVIA team
Download
CCC 2020 - Blue Book on the internationalization of china's pharmaceutical industry
November 2020
Presented by
China Chamber of Commerce for Import & Export of Medicines &Health Products and China Office of Clarivate Analytics
Download
CPhI China Report 2020 - IQVIA
September 2020
Presented by
CPhI and IQVIA team
Download
ANNUAL HIGHLIGHTS OF CHINA'S HEALTHCARE INDUSTRY
February 2020
Presented by
China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)
Download
GBI - Year in Review 2019 China's new drug approvals
January 2020
Presented by
Robert McTiernan
Download
Asia Pacific as a Clinical Trials Powerhouse
October 2022
Presented by
Citeline (Pharma Intelligence)
Download
Pharma R&D Annual Review 2022 Supplement: New Active Substances Launched During 2021
October 2022
Presented by
Citeline (Pharma Intelligence)
Download
Pharma R&D Annual Review 2022: Navigating the Landscape
October 2022
Presented by
Citeline (Pharma Intelligence)
Download
The Annual Clinical Trials Round-up 2021-Clinical Trials Resilience After Pandemic Disruptions
October 2022
Presented by
Informa Pharma Intelligence
Download
China Clinical Trials Landscape 2021
September 2021
Presented by
Informa Pharma Intelligence
Download
2021Sustainability in Pharma Packaging, Devices and Manufacturing Report
December 2021
Presented by
CPHI Online
Download
CPhI Pharma 2021 Annual Report- Golden Age for Discovery, Technology and Growth
December 2021
Presented by
CPHI Online
Download
CPhI China and IQVIA Market Prognosis 2021- 2025
September 2021
Presented by
CPhI and IQVIA team
Download
CCC 2020 - Blue Book on the internationalization of china's pharmaceutical industry
November 2020
Presented by
China Chamber of Commerce for Import & Export of Medicines &Health Products and China Office of Clarivate Analytics
Download
CPhI China Report 2020 - IQVIA
September 2020
Presented by
CPhI and IQVIA team
Download
ANNUAL HIGHLIGHTS OF CHINA'S HEALTHCARE INDUSTRY
February 2020
Presented by
China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)
Download
GBI - Year in Review 2019 China's new drug approvals
January 2020
Presented by
Robert McTiernan
Download
More
The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases
#Drug Review #R&D #Business
The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases
EPISODE 30 |  16 MIN  |  22 Nov. 2022
The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. Looking back on this week's pharma news, BeiGene's new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui's JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases.
Play
NMPA Nod Gives YL-Pharma First Highly Selective PI3Kδ Inhibitor Marketing Approval in China
#Drug Review #R&D #Business
NMPA Nod Gives YL-Pharma First Highly Selective PI3Kδ Inhibitor Marketing Approval in China
EPISODE 29 |  14 MIN  |  15 Nov. 2022
This week, the first highly selective PI3Kδ inhibitor in China, linperlisib of YL-Pharma, was approved for marketing. Multiple positive results have been released from several clinical trials, but GSK announced that the Phase III superiority trial of its BCMA ADC combined with pomalidomide in the treatment of relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival (PFS). Jumpcan Pharmaceutical entered into a cooperation agreement with Newsoara and obtained the development rights of two innovative drugs.
Play
The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China
#Drug Review #R&D #Business
The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China
EPISODE 28 |  14 MIN  |  08 Nov. 2022
This week, Toludesvenlafaxine Hydrochloride Extended-Release Tablets, a kind of first-in-class anti-depressant drug developed by the Chinese company Luye Pharma, was approved for marketing. In terms of R&D, the phase III clinical research of PCSK9 Monoclonal Antibody developed by Akeso met the endpoints and was planned to apply for marketing. In terms of business, SonnetBio and Janssen, a subsidiary of Johnson & Johnson, reached a cooperation agreement on three candidate products.
Play
The Marketing Declaration of HAISCO's Novel Analgesic for Diabetic Peripheral Neuralgia Treatment
#Drug Review #R&D #Business #Listing #COVID-19
The Marketing Declaration of HAISCO's Novel Analgesic for Diabetic Peripheral Neuralgia Treatment
EPISODE 27 |  13 MIN  |  01 Nov. 2022
The marketing application of HAISCO's first-in-class HSK16149 Capsule was submitted, presumably for the treatment of diabetic peripheral neuralgia. While in the global markets, Simcere Pharmaceutical's SIM0237 had been approved for clinical use in the United States for the treatment of locally advanced unresectable or metastatic solid tumors. In terms of R&D, several clinical trials achieved positive results, while Alpine Immune terminated two clinical trials of davoceticept due to the death of patients.
Play
You can get more engaged!
Become a Speaker
Share your voice at our diverse digital or
on-site events
Submit Bio and Topic
Become a Writer
Express your unique insights as a KOL in the
pharmaceutical community
Contact Editorial Team
Become a Partner
Broaden business outreach
in the second largest pharma market
Learn More
EZBuy
Livestream & Activity
Conference & Forum
PharmaSources Customer Service